News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
VIVEbiotech has completed the latest expansion phase of its lentiviral vector manufacturing capabilities; the development is aimed at alleviating the viral vector bottleneck for advanced therapies.
Australian biotech Skin2Neuron’s new form of cell therapy reversed a dementia-like syndrome in dogs, according to results of a veterinary trial.
A new ‘European Union – Latin America and Caribbean’ partnership aims to boost Latin America’s manufacturing capacity.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) made several recommendations for approval of drugs and therapies at its June 2022 meeting.